Cytokinetics, Incorporated (NASDAQ: CYTK) experienced a notable stock decline on Friday morning, with shares falling 5.0% to $74.00 as of 10:08 a.m. EDT. This drop erased approximately $515 million in market value, reflecting investor disappointment despite the company announcing the first successful Phase 3 clinical trial for a treatment targeting non-obstructive hypertrophic cardiomyopathy (nHCM).
The pivotal study, known as ACACIA-HCM, evaluated the efficacy of MYQORZO (aficamten) in 517 patients with symptomatic nHCM. At the 36-week mark, the trial met both primary endpoints. Patients receiving MYQORZO experienced a 3.0-point greater improvement in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) compared to those on placebo (11.4 vs. 8.4 points). Additionally, peak oxygen consumption (VO2) increased by 0.64 ml/kg/min in the treatment group, while the placebo group saw a slight decrease of 0.03 ml/kg/min, resulting in a statistically significant difference of 0.67 ml/kg/min.
Secondary endpoints also favored MYQORZO. A higher proportion of treated patients achieved at least one New York Heart Association (NYHA) functional class improvement (41.9% vs. 27.8%). The drug also reduced levels of a cardiac-stress biomarker. However, no significant effect was observed on left-atrial volume or time to first cardiovascular event.
Dr. Stephen Heitner, Chief Medical Officer of Cytokinetics, hailed ACACIA-HCM as the “first-ever positive clinical trial in non-obstructive HCM,” underscoring the potential significance for the company and the patient community. The company plans to submit a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) in the fourth quarter of this year.
If approved, MYQORZO would expand Cytokinetics' commercial footprint, which is still in its early stages. The drug generated $25.3 million in product revenue during the second quarter. As of June 30, approximately 1,500 patients had been treated with MYQORZO, and over 700 prescribers had written prescriptions. The launch has been resource-intensive, with selling and administrative expenses climbing 59% to $104.4 million in the quarter. Management has raised its full-year 2026 research and commercial cost guidance to between $860 million and $890 million.
Despite the spending, Cytokinetics maintains a solid balance sheet. Following a $760 million share sale, the company holds roughly $1.7 billion in cash and investments. In the second quarter, it reported a net loss of $198.8 million.
Wall Street remains broadly optimistic about the stock. Of 22 analysts surveyed, 20 rate it a “buy” and two a “hold,” with an average price target of $109.90, representing a 48.5% upside from Friday's last close. However, the market's reaction suggests that investors were hoping for more robust efficacy data.
The focus now shifts to the commercial potential versus the clinical profile. While a broader label could significantly expand MYQORZO's addressable market, physicians must weigh the modest absolute improvements against safety concerns. In the trial, 10.5% of aficamten-treated patients experienced a drop in left ventricular ejection fraction (LVEF) below 50%, compared to 0.8% in the placebo group. The incidence of serious adverse events was also higher in the treatment arm, which regulators will scrutinize when assessing the risk-benefit ratio.
As Cytokinetics prepares for its FDA submission, the investment community will closely monitor regulatory discussions and the drug's performance in the real-world setting. The coming months will be crucial in determining whether MYQORZO can fulfill its promise as a transformative therapy for non-obstructive HCM.
